Government Cracks Down on Pharma Industry

The Feds are signaling that pharma firms must do much more self-policing regarding their marketing practices—including those involving meetings—or risk federal prosecution under anti-kickback regulations. Specifically, the government is targeting the provision of financial incentives to healthcare professionals to prescribe or recommend particular drugs, or to switch patients from one medicine to another. The Department of Health and Human Services (HHS) Inspector General Janet Rehnquist a

Register to view the full article

Register for MeetingsNet.com and gain access to premium content including the CMI 25 Listing, our monthly digital edition, the MeetingsNet app, live and on-demand webinars, and much more.

Already a member? .

Hide comments

Comments

  • Allowed HTML tags: <em> <strong> <blockquote> <br> <p>

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Publish